Evidence map›Paper›PMID 26295742›Full record

ArticleBiochemistry2015

Platelet Lipidomic Profiling: Novel Insight into Cytosolic Phospholipase A2α Activity and Its Role in Human Platelet Activation.

Matthew T Duvernay, Anton Matafonov, Craig W Lindsley, Heidi E Hamm

Open access · greenAbstract read
In one paragraph

Article in Biochemistry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Research (Washington, D.C.) · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. The Link between Prostanoids and Cardiovascular Diseases.International journal of molecular sciences · 2023
    Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Matthew T DuvernayDepartment of Pharmacology, Vanderbilt University , Nashville, Tennessee 37232, United States.
Anton MatafonovHematology/Oncology, Vanderbilt University , Nashville, Tennessee 37232, United States.
Craig W LindsleyCenter for Neuroscience Drug Discovery, Vanderbilt University , Nashville, Tennessee 37232, United States.
Heidi E HammDepartment of Pharmacology, Vanderbilt University , Nashville, Tennessee 37232, United States.
Vanderbilt University · US

Funding

THE PHARMACOLOGY OF ASPIRINP50HL081009 · NHLBI · VANDERBILT UNIVERSITY · PI LIEBLER, DANIEL · 2006 to 2010
$16.3M
Targeting PAR4 in Thrombotic Disorders:Pharmacogenomic ApproachR01HL133923 · NHLBI · VANDERBILT UNIVERSITY · PI HAMM, HEIDI E · 2017 to 2020
$2.3M
Optimization of PAR4 antagonists for thrombotic disordersR01NS081669 · NINDS · VANDERBILT UNIVERSITY · PI HAMM, HEIDI E · 2013 to 2015
$1.0M
Screening for allosteric modulators of the protease activated receptor 4R01NS082198 · NINDS · VANDERBILT UNIVERSITY · PI HAMM, HEIDI E · 2013 to 2015
$1.0M
NHLBI NIH HHS P50 HL081009NHLBI NIH HHS R01 HL133923NINDS NIH HHS R01 NS081669NINDS NIH HHS R01 NS082198
6 · The paper itself

Abstract

With a newer, more selective and efficacious cytosolic phospholipase A2α (cPLA2α) inhibitor available, we revisited the role of cPLA2α activity in platelet activation and discovered that a component of platelet signaling, even larger than previously appreciated, relies on this enzyme. In a whole blood shear-based flow chamber assay, giripladib, a cPLA2α inhibitor, reduced platelet adhesion and accumulation on collagen. Moreover, giripladib differentially affected P-selectin expression and GPIIbIIIa activation depending on the agonist employed. While protease-activated receptor 1 (PAR1)-mediated platelet activation was unaffected by giripladib, the levels of PAR4- and GPVI-mediated platelet activation were significantly reduced. Meanwhile, the thromboxane A2 receptor antagonist SQ29548 had no effect on PAR-, GPVI-, or puriniergic receptor-mediated platelet activation, suggesting that another eicosanoid produced downstream of arachidonic acid liberation by cPLA2α was responsible for this large component of PAR4- and GPVI-mediated platelet activation. In parallel, we profiled PAR-mediated changes in glycerophospholipid (GPL) mass with and without giripladib to better understand cPLA2α-mediated lipid metabolism. Phosphatidylcholine and phosphatidylethanolamine (PE) demonstrated the largest consumption of mass during thrombin stimulation. Additionally, we confirm phosphatidylinositol as a major substrate of cPLA2α. A comparison of PAR1- and PAR4-induced metabolism revealed the consumption of more putative arachidonyl-PE species downstream of PAR1 activation. Instead of enhanced cPLA2α activity and therefore more arachidonic acid liberation downstream of PAR4, these results indicate the major role that cPLA2α activity plays in platelet function and suggest that a novel eicosanoid is produced in response to platelet activation that represents a large component of PAR4- and GPVI-mediated responses.

Indexed as

BenzoatesBlood PlateletsGlycerophospholipidsGroup IV Phospholipases A2HumansLipidsOligopeptidesPeptide FragmentsPlatelet ActivationPlatelet Membrane GlycoproteinsReceptor, PAR-1Receptors, ThrombinSpectrometry, Mass, Electrospray IonizationStress, MechanicalSulfonamidesThrombinalanyl-tyrosyl-prolyl-glycyl-lysyl-phenylalanineBenzoatesGlycerophospholipidsGroup IV Phospholipases A2LipidsOligopeptidesPeptide FragmentsPLA-695Platelet Membrane Glycoproteinsplatelet membrane glycoprotein VIprotease-activated receptor 4Receptor, PAR-1Receptors, ThrombinSulfonamidesThrombinthrombin receptor peptide (42-47)

Identifiers

PMID26295742
PMCPMC7748375
OpenAlexW2405152345

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.